An Open-Label Trial of Vesicare(Solifenacin Succinate) for the Treatment of Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

An Open-Label Trial of Vesicare(Solifenacin Succinate) for the Treatment of Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) - Effect of Vesicare on IBS-D

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005577

Enrollment

Registered

2011-05-09

Start date

2011-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

Interventions

One 5 mg Vesicare tablet taken orally per day for 2 weeks. If IBS symptoms for the last week improve, continue the dose for additional 4 weeks. If not, two 5mg tablets are taken for addtional 4 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects must have been diagnosed with IBS-D by a physician (Rome III Criteria). Subject must be outpatients and be over 20 years of age.

Exclusion criteria

Exclusion criteria: Uncontrolled heart disease or arrhythmias. History of major gastrointestinal surgery. Urinary retention. Narrow angle glaucoma. myasthenia gravis. Severe constipation.

Design outcomes

Primary

Measure	Time frame
IBS symptoms of week 6 and IBS symptoms at week 0 (before the start of Vesicare)	—

Secondary

Measure	Time frame
IBS symptoms for the last week	—

Countries

Japan

Contacts

Public ContactYasushi Fukushima

Tokyo-Eki Center-building Clinic Department of Internal Medicine

Yasushi.fukushima.c@tec-c.jp03-3517-6688

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026